Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 3Unknown 1Terminated 1Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 14Gastrointestinal 4Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Classical hematology 1CNS 1

Conditions

Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 80Radiotherapy 41Bevacizumab 35Radiosurgery 23Magnetic Resonance Spectroscopy 20Cyclophosphamide 17Radiation 14Irinotecan 13Carboplatin 12Topotecan 11Nivolumab 11Lomustine 11Filgrastim 10Everolimus 10Etoposide 10Erlotinib Hydrochloride 10pembrolizumab 9Radiotherapy, Intensity-Modulated 9Ipilimumab 9Granulocyte Colony-Stimulating Factor 8Carmustine 8antineoplaston AS 2-1 7antineoplaston A10 7Surgical Procedures, Operative 7Mental Status and Dementia Tests 7Isotretinoin 7Granulocyte-Macrophage Colony-Stimulating Factor 7sargramostim 6Vincristine 6TPI-287 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Ado-Trastuzumab Emtansine × CNS × Clear all
NCT03190967 2023-10-11

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
12 enrolled 16 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡